麝香保心丸治疗冠心病心绞痛的临床观察

Clinical Observation of Shexiang Baoxinwan for Treatment of Coronary Heart Disease with Angina Pectoris

将２１０例冠心病心绞痛患者随机分为麝香保心丸治疗组（１１０例）和消心痛对照组（１００例）。两组在年龄、心绞痛分型、合并病变及心功能分级分布均相仿，前者给予麝香保心丸２丸，每日３次口服；后者给予消心痛５～１０ｍｇ，每日３次口服，经２周治疗，二药均可显著降低心绞痛发作频率和硝酸甘油日耗量，并显著改善心电图ＳＴ压低总和（ＳＴ）改变。但是总的症状疗效、心电图疗效和不良反应则麝香保心丸明显优于消心痛。即症状疗效分别为９０．０％与７６．０％（Ｐ＜０．０５）；心电图疗效５８．６％与４０．８％（Ｐ＜０．０５），头痛发生率０．９％与１７．０％（ｐ＜０．０１）。此外，二药起效迅速，分别有８６．３％与８３．４％的患者在５ｍｉｎ内生效，基本相仿。

Two hundred and ten patients with angina pectoris in coronary heart disease were randomly assigned to receiving Shexiang Baoxinwan(SXBXW),the protecting heart musk pills(110 patients),or receiving isosorbide dinitrate(100 patients) for 2 weeks. They were well matched for age,afiginal types,complications and cardiac functional grading.The results demonstrated that both agents not only could reduce significantly the frequencies of anginal episodes and the consuniption amount of nitroglycerin per day, they also could result in significant improvement of the ST segment depression in electrocardiogram.Furthermore,the SXBXW had better efficacy than that of isosorbide dinitrate in the total improvement rate of symptoms of angina pectoris and of ECG,and in the reduction of incidence of headache,ie 90.0% vs.76.%;58.6% vs.40.8%;0.9% vs.17%,respectively(P<0.05 or P<0.01).In addition,the onset of action of both agents was rapid,within five minutes(83.4% in patients using SXBXW vs.86.3% in control group,P>0.05).